Our board members bring extensive experience across the Australian healthcare and medical sector, and biotechnology industry.
Matt O’Keefe
Chair
Matt O’Keefe is a Board Director of the Peter MacCallum Cancer Centre and the Chairman of the Finance Committee. With more than 25 years’ technology, finance and assurance experience, he specialises in technology advisory and offers numerous services across technology governance and risk, project management, and more.
Deirdre Blythe
Director
Deirdre’s career spans executive and non-executive roles across the commercial, government, and NFP sectors. She was COO at Arts Centre Melbourne for eight years until August 2023 and was Non-Executive Director at the Peter MacCallum Cancer Centre, chairing the Audit and Risk Management Committee. Deirdre is a Fellow of the Australian Institute of Company Directors and Institute of Chartered Accountants.
Libby Secomb
Director
With over 20 years’ experience, Libby is a Finance professional with a demonstrated history of working in the financial services industry. She is skilled in operational leadership, Financial Risk, Internal Audit, Risk Management, and Corporate Finance. Before her successful career as a finance and accounting professional, Libby was a medical laboratory scientist at the Royal Children’s Hospital.
Michelle Burke
Non-Executive Director
Michelle has Board and Executive experience in the pharmaceuticals and biotechnology sector. She is a Non-executive Director at Olivia Newton-John Cancer Research Institute, and a member of Pharmaceutical Benefits Advisory Committee (PBAC). She also served on the Board at AusBiotech Ltd for nine years, including a period as its Chair.
Cell Therapies is led and supported by an extensive team of experts from across the medical, healthcare and scientific communities to drive the development and commercialization of groundbreaking cell and gene therapies.
Dedicated and experienced cell and gene therapy experts driving your product from clinical trial to commercial supply
Expertise and knowledge across cell and gene therapies as well as the health and medical sector
